obesity and response to hepatitis c therapy n.
Skip this Video
Download Presentation
Obesity and Response to Hepatitis C Therapy

Loading in 2 Seconds...

play fullscreen
1 / 25

Obesity and Response to Hepatitis C Therapy - PowerPoint PPT Presentation

  • Uploaded on

Obesity and Response to Hepatitis C Therapy. Hossam Kandil Gastroenterology& Nutrition University of Pittsburgh May 2010. Natural History of Hepatitis C. Acute Hepatitis C. 10-20 years. Chronic Hepatitis 75%-85 %. Cirrhosis 20 %. Annual rate. Decompensation 3-6 %.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Obesity and Response to Hepatitis C Therapy' - cynara

Download Now An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
obesity and response to hepatitis c therapy

Obesity and Response to Hepatitis C Therapy

Hossam Kandil

Gastroenterology& Nutrition

University of Pittsburgh

May 2010

natural history of hepatitis c
Natural History of Hepatitis C

Acute Hepatitis C

10-20 years

Chronic Hepatitis

75%-85 %

Cirrhosis 20 %

Annual rate

Decompensation 3-6 %

treatment of hepatitis c
Treatment of Hepatitis C
  • Currently approved standard treatment is combination of PEG-Interferon-a + Ribavirin
  • Treatment is for 6 or 12 months (based on genotype)
  • Overall Response (SVR) 50%
  • Genotype-1 & 4 40%
  • Genotype-2 80%
  • Genotype-3 70%
  • SVR = Sustained Virological Response

Independent factors associated with an SVR

Multiple Logistic Regression Analysis


Odds Ratio (95% CI)

No effect on SVR

Greater effect on SVR

Randomizes control Study of Peg-INFa2a versus IFNa2a 3X/week

(BMI (> vs ≤ 28) and weight > vs ≤85 kg were NOT risk factors)

Zeuzem S. NEJM 2000;343:1666-72.

weight and response to hepatitis c treatment
Weight and Response to Hepatitis C treatment

Prospective study of 145 patients with CHC

  • 95% Caucasian, 5% Asian
  • IFN, PEG-IFN, or IFN + Ribavirin.
  • Only those who completed 80% of therapy
  • Obese = >30 for Caucasians or > 25 for Asians

Factors Associated with Non-Response

OR (95% CI)

Genotypes 1 & 4 4.1 (1.9 – 8.9)*

Cirrhosis 3.2 (1.2 – 9.0)*

Obesity 3.9 (1.4 – 11.2)*

Walsh MJ. Gut 2006;55:529-35

risk factors for non response to hepatitis c treatment
Risk Factors for Non-Response to Hepatitis C Treatment
  • Genotype 1 & 4
  • Presence of advanced fibrosis/cirrhosis
  • Age
  • High viral load
  • Ethnicity
  • Steatosis
  • Obesity
how does obesity decrease response to hepatitis c treatment
How does Obesity decrease Response to Hepatitis C Treatment?
  • Lower dose/body weight
  • Larger volume of Distribution
  • Poor lymphatic drainage from subcutaneous tissue.
  • Associated Metabolic Syndrome with steatosis and increased fibrosis
  • Impaired biological response to interferon.

Metabolic Syndrome

Obesity (Central)

Diabetes, HTN


Fatty liver Disease

Insulin Resistant State


Fat-Derived Factors

Regulate Hepatic Inflammatory Response














Metabolic Syndrome

Abnormal production of hormones & cytokines that regulate inflammatory responses




IL-1, IL-6




steatosis and hepatitis c
Steatosis and Hepatitis C
  • In studies of liver biopsies of HCV patients with known date of infection
  • Obesity (BMI) is associated with steatosis
  • Central adiposity is associated with steatosis and higher fibrosis progression
  • Hepatitis C patients with steatosis have: Increased inflammation and fibrosis

Higher annular rate of fibrosis progression

  • Adinolfi LE, Hepatol 2001;33:1358-
  • Hourigan LF, Hepatology 1999, 29:1215-
metabolic syndrome
Metabolic Syndrome
  • Inflammation in obesity modulates inflammatory response to IFN

suppressors of IFNa activity (e.g. SOCS).

TH-1 to TH-2

  • Increased TNFa and Leptin resistance associated with non-response to treatment.
effect of weight management
Effect of Weight management

If obese subjects do not respond to standard hepatitis C treatment;

Can weight management improve response to Hepatitis C treatment??


Early Weight Loss During Pegylated Interferon Therapy of Treatment-Naïve Hepatitis C is Associated with Improved Virological Response

Hany Alwakeel MD, Hassan Zaghla MD PhD, Nabeel Omar MD PhD, Hassan Alshinnawy MD PhD, Eman Rewisha MD PhD, Azza Taha MD, Stephen O’Keefe MD MSc, Toby Graham MD, Hossam Kandil MD, PhD

National Liver Institute, Shibin Alkom, Menofeya, Egypt

University of Pittsburgh Medical Center, Pittsburgh, PA

JPEN 2010, H44-6

rationale objective
  • Spontaneous weight loss is commonly experienced during PEG-IFN + Ribavirin combination therapy.
  • We examined whether treatment-associated weight loss during PEG-IFN + Ribavirin therapy is associated with improved response rate.
  • Patients were categorized into 2 groups:
    • Weight loss group (WL)
    • No-weight loss group (NWL)

- Weight loss = BMI decreased by 0.5 kg/m2 or more versus pre-treatment BMI


Viral response rates compared among WL and NWL

  • Rapid Virological Response (RVR)

Viral clearance at 4 weeks

  • Early Virological Response (EVR)

2 log drop in viral load at 12 weeks

  • End of Treatment Response (ETR)

Viral clearance at 48 weeks

  • Sustained Virological Response (SVR)

Viral clearance at 72 wks

RVR and EVR significantly associated with SVR

effect of weight loss at 1 month on virological responses
Effect of Weight Loss at 1 month onVirological Responses


  • RVR 50% 43.5% 0.1
  • EVR 83.8%* 76.2% 0.01
  • ETR 71%* 63.6% 0.02
  • SVR 55.3% 48.4% 0.1
effect of weight loss at 3 months on virological responses
Effect of Weight Loss at 3 months on Virological Responses


  • EVR 89.4%* 76.2% 0.02
  • ETR 73.2% 69% 0.6
  • SVR 59.3% 47.9% 0.2
factors associated with virological responses
Factors Associated with Virological Responses


Age Wt loss @ 1 m* Genotype*

Race Wt loss @ 3 m *Age*

Viral load Age Longer Treat*

Genotype* Longer Treat *Viral load*




* Independently associated with +ve response by multivariate regression analysis

  • Spontaneous weight loss during the first 3 months of PEG-IFN + Ribavirin therapy is associated with improved early virological response.
  • Weight management programs at the beginning of PEG-IFN + Ribavirin therapy may improve virological response.

Effects of dietary and behavioral management of obesity and metabolic syndrome on response to Hepatitis C therapy

Randomized, Double Blind, Placebo Controlled Pprospective Study.

intervention group bmi 30
Intervention Group (BMI ≥ 30)

Standard 12 month treatment

Pegylated Interferon + Ribavirin

Monthly follou up cessions

Nutr Education